Two new indications for Gaviscon

The licence for Gaviscon Advance (sodium alginate, potassium bicarbonate) aniseed suspension has been extended.

It can now be used to treat of symptoms of gastro-oesophageal reflux during concomitant treatment with acid suppressing therapy and symptoms of laryngopharyngeal reflux.

View Gaviscon Advance drug record

Further information: Reckitt Benckiser

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more